, Volume 77, Issue 1, pp 58–65 | Cite as

Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate

  • A. Jørgensen
  • J. Andersen
  • N. Bjørndal
  • S. J. Dencker
  • L. Lundin
  • U. Malm
Original Investigations


Nine chronic schizophrenic patients selected from three hospital departments were treated with flupentixol (orally and IV) and cis(Z)-flupentixol decanoate in Viscoleo (IM) in a three-phase pharmacokinetic study. Oral administration (single and repeated dosage) showed a relatively slow absorption with maximum serum concentration around 4 h after administration. Intravenous injection indicated multicompartment kinetics for cis(Z)-flupentixol. The biological half-lives calculated after the different doses were the same, indicating that the pharmacokinetics of cis(Z)-flupentixol does not differ between single and repeated administration and does not change when moderately higher doses are given. The bioavailability of orally administered cis(Z)-flupentixol was calculated to be about 40% with IV injection as reference. After IM administration maximum serum concentration was seen between 4 and 10 days in most patients. Calculation of a disappearance half-life gave very variable results, indicating that the release of the drug from the oil depot is not a monoexponential process. The intramuscular depot had a much lower bioavailability than IV injection, which means that steady state has not been obtained after 8 weeks of depot treatment. Serum prolactin concentrations were elevated during neuroleptic treatment, but no correlation was found between prolactin concentrations and the serum concentrations of cis(Z)-flupentixol. A correlation between the changes in clinical ratings and concentrations of cis(Z)-flupentixol or prolactin was not found.

Key words

Neuroleptic Flupentixol Flupentixol decanoate Serum levels Prolactin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beumont PVJ, Corker CS, Friesen HG, Kolakowska T, Mandelbrot BM, Marshall J, Murray MAF, Wiles DH (1974) The effects of phenothiazines on endocrine function: II. Br J Psychiatry 124:420–430Google Scholar
  2. Bjerkenstedt L, Eneroth P, Härnryd C, Sedvall G (1977) Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic. Arch Psychiat Nervenkr 224:281–293Google Scholar
  3. Bjørndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, Wæhrens J (1980) High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol and serum prolactin. Psychopharmacology 67:17–23Google Scholar
  4. Curry SH, Whelpton R, De Schepper PJ, Vranckx C, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, fluphenazine enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325–331Google Scholar
  5. Curry SH, Altamura AC, Montgomery S (1979) Unwanted effects of fluphenazine enanthate and decanoate. Lancet 331–332Google Scholar
  6. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shabid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 73:205–210Google Scholar
  7. Eggert Hansen C, Rosted Christensen T, Elley J, Hansen LB, Kragh-Sørensen P, Larsen N-E, Naestoft J, Hvidberg EF (1976) Pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 3:915–923Google Scholar
  8. Forsman A, Øhman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396–411Google Scholar
  9. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No(ADM) 76-338. National Institute of Mental Health, RockvilleGoogle Scholar
  10. Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 848–851Google Scholar
  11. Jørgensen A, Hansen V, Dahl Larsen U, Rauf Khan A (1969) Metabolism, distribution and excretion of flupentixol. Acta Pharmacol Toxicol 27:301–313Google Scholar
  12. Jørgensen A, Fredricson Overø K, Hansen V (1971) Metabolism, distribution and excretion of flupentixol decanoate in dogs and rats. Acta Pharmacol Toxicol 29:339–358Google Scholar
  13. Jørgensen A (1978) A sensitive and specific radioimmunoassay for cis(Z)-flupentixol in human serum. Life Sci 23:1533–1542Google Scholar
  14. Jørgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis(Z)-flupentixol and intramuscular cis(Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol 18:355–369Google Scholar
  15. Jørgensen A, Fredricson Overø K (1980) Clopenthixol and flupentixol depot preparations in outpatients schizophrenics, III. Serum levels. Acta Psychiat Scand Suppl 279:41–54Google Scholar
  16. Kazuko I, Narischige T, Moinoru I (1976) Determination of prolaction levels in blood by radioimmunoassay (double antibody system). Internal Department No 1. Faculty of Medicine. Toho University, Japan. Preclinical ReportGoogle Scholar
  17. Kendall MG, Stuart A (1973) The advanced theory of statistics, vol 2. Charles Griffin & Co Ltd, LondonGoogle Scholar
  18. Kolakowska T, Wiles DH, Gelder MG, McNeilly AS (1976) Clinical significance of plasma chlorpromazine levels. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment. Psychopharmacology 49:101–107Google Scholar
  19. Langer G, Sachar EJ, Halpern FS, Gruen PH, Solomon M (1977) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab 45:996–1002Google Scholar
  20. May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry 35:1081–1087Google Scholar
  21. Meltzer HY, Fang VS (1976) The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33:279–286Google Scholar
  22. Molnar G, Gupta RN (1980) Plasma levels and tricyclic antidepressant therapy. Part 2. Pharmacokinetic, clinical and toxicologic aspects. Biopharm Drug Disp 1:283–305Google Scholar
  23. Muusze RG, Visser-Van der Weel AJ, Verzijden R, Oei TT (1977) Fluorimetrische bepaling op de dunne laag van de bloodkoncentratie van thioxanthenen (Sordinol en Fluanxol) na orale en intramusculaire (depot) toedining. Bulletin van de coördinatiecommissie biochemisch inderzoek van de psykiatrische instituten van de nationale ziekenhuisraad 10:1–8Google Scholar
  24. Møller Nielsen I, Pedersen V, Nymark M, Franck KF, Boeck V, Fjalland B, Christensen AV (1973) The comparative pharmacology of flupentixol and some reference neuroleptics. Acta Pharmacol Toxicol 33:353–362Google Scholar
  25. Naber D, Fischer H, Ackenheil M (1979) Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: Development of tolerance? Commun Psychopharmacol 3:59–65Google Scholar
  26. Nasrallah HA, Rivera-Calimlim L, Rogot AD et al. (1978) Fluphenazine decanoate: Plasma concentrations and clinical response. Psychopharmacol Bull 14:46–47Google Scholar
  27. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812Google Scholar
  28. Rivera-Calimlim JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976a) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol 5:273–282Google Scholar
  29. Rivera-Calimlim L, Nasrallah H, Strauss J, Lasagna L (1976b) Clinical response and plasma levels: Effect of dose, dosage schedule, and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 133:646–652Google Scholar
  30. Schneider K (1959) Psychischer Befund und psychiatrische Diagnose. Klinische Psychopathologie, 5 Aufl., Leipzig, ThemeGoogle Scholar
  31. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiat Scand Suppl 212:11–19Google Scholar
  32. Stauning JAa, Kirk L, Jørgensen A (1979) Comparison of serum levels after intramuscular injection of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients. Psychopharmacology 65:69–72Google Scholar
  33. Wiles DH, Kolakowska T, McNeilly AS, Mandelbrot BM, Gelder MG (1976) Significance of plasma chlorpromazine levels, I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychol Med 6:407–415Google Scholar
  34. Wiles DH (1979) Tardive dyskinesia and depot fluphenazine. Br J Psychiatry 382–383Google Scholar
  35. Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8:565–570Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • A. Jørgensen
    • 1
  • J. Andersen
    • 2
  • N. Bjørndal
    • 3
  • S. J. Dencker
    • 4
  • L. Lundin
    • 4
  • U. Malm
    • 4
  1. 1.Biochemical DepartmentH. Lundbeck & Co. A/SCopenhagen-ValbyDenmark
  2. 2.Department ESct. Hans HospitalRoskildeDenmark
  3. 3.Department HSci. Hans HospitalRoskildeDenmark
  4. 4.Department IILillhagen HospitalGothenburgSweden

Personalised recommendations